Quantcast

Posts related to ‘Provenge’

Food and Drug Administration logo

Dendreon Gets Prostate Cancer Competition for Provenge from Bayer’s Xofigo

Posted: May 15, 2013 at 11:15 am

Dendreon Corp. (NASDAQ: DNDN) has been facing problems getting its Provenge sales for advanced metastatic prostate cancer through to the market. Even a direct to consumer advertising campaign has so ...
Read Full Story »
biotech

Dendreon Shows Poor Provenge Sales, Implosion Risk Rising

Posted: May 9, 2013 at 10:25 am

Dendreon Corp. (NASDAQ: DNDN) just cannot catch a break. Despite having what was supposed to be one of the best late-stage prostate treatments in Provenge, sales just are not coming ...
Read Full Story »
biotech

Can Dendreon’s Stock Really Double Again?

Posted: January 11, 2013 at 2:16 pm

Dendreon Corp. (NASDAQ: DNDN) is seeing shares surge higher on Friday on an analyst upgrade. The move higher is part because Dendreon has a long history of boom and bust ...
Read Full Story »

Some Added Hope For Dendreon

Posted: May 21, 2012 at 12:12 pm

Dendreon Corporation (NASDAQ: DNDN) needs all the goods news it can get.  While the American Society for Clinical Oncology (ASCO) has its annual meeting in les than two weeks and ...
Read Full Story »

Dendreon Rises on Takeover Chatter (DNDN, LLY, AMGN)

Posted: March 21, 2012 at 12:46 pm

Dendreon Corp. (NASDAQ: DNDN), maker of prostate cancer drug Provenge, is once again rumored to be a takeover target. As Streetinsider.com points out, the company’s new chairman presided over the ...
Read Full Story »

Dendreon Raising $125 Million Via I.P. Sale (DNDN, MRK)

Posted: December 6, 2011 at 12:45 pm

Dendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment.  Unfortunately, PROVENGE sales ran slower than expected after the FDA took forever to ...
Read Full Story »

Another Bump Up for Dendreon and PROVENGE (DNDN)

Posted: November 21, 2011 at 8:38 am

Dendreon Corporation (NASDAQ: DNDN) is surging on news that the Centers for Medicare and Medicaid Services will now cover the infusion costs associated with the administration of PROVENGE.  Dendreon noted ...
Read Full Story »

Picking Apart the Dendreon Implosion (DNDN)

Posted: August 4, 2011 at 7:59 am

Dendreon Corporation (NASDAQ: DNDN) was supposed to be the Holy Grail when it comes to investing in a treatment for prostate cancer.  The limited life-extension versus a high cost for ...
Read Full Story »

BioWatch: Dendreon Looks Even Brighter (DNDN)

Posted: April 1, 2011 at 12:17 pm

Earlier this week, we highlighted Dendreon Corporation (NASDAQ: DNDN) as one of five biotechs with 50% implied upside.  A new report is out from Canaccord Genuity that has figures which ...
Read Full Story »